Physician profile
Kumar Satya
NPI 1710163357
$3,361.71
in general payments reported to CMS, 2019-2025
17 companies · $678 in 2025
The $678 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $22.63 · 2021: $40.21 · 2022: $73.57 · 2023: $237 · 2024: $866 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,520.00 | 2019-2025 | Impella |
| Abbott Laboratories | $647.18 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Ancora Heart, INC. | $547.64 | 2024-2025 | Accucinch |
| Daxor Corporation | $252.26 | 2024-2025 | Bva-100 |
| Novartis Pharmaceuticals Corporation | $115.81 | 2023-2024 | |
| Nxstage Medical, INC. | $77.99 | 2025 | Nxstage System One |
| Boston Scientific Corporation | $32.84 | 2024 | |
| Edwards Lifesciences Corporation | $30.53 | 2024 | Hemosphere |
| Cvrx, INC. | $28.48 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $28.33 | 2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.26 | 2021 | |
| Liquidia Technologies, INC. | $22.44 | 2025 | Yutrepia |
| Alnylam Pharmaceuticals INC. | $18.00 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $11.95 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Satya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.